https://www.selleckchem.com/pr....oducts/l-685-458.htm
5Gy (range, 59.4-76.0Gy). The ORR for all patients was 71%, and complete response/partial response were 50%/25% in R-SCC and 8%/62% in R/LA-nSCC. The 2-year overall survival for R-SCC and R/LA-nSCC were 58% and 100%, respectively. The median LRPFS was 11.5months for R-SCC. Frequently observed adverse events included alopecia (95%), hyperamylasemia (86%), and nausea (81%). These data suggest that BNCT using C-BENS with borofalan ( is a promising treatment option for patients with R-SCC or R/LA-nSCC of the head and neck. These data s
Like
Comment
Share
